VolitionRx reports strong second quarter as it moves forward on key MoUs

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds caught up with Proactive London's Andrew Scott to discuss the group's second quarter update.

Reynolds says they've continued to strengthen the balance sheet with cash and cash equivalents increasing significantly thanks to warrant exercises by investors.

He adds they're now looking to advance the previously announced large-scale colorectal cancer trials in Europe, the US and Asia as well as the clinical trial program for lung cancer.

Quick facts: VolitionRx

Price: $4.18

Market Cap: $171.76 m


VolitionRx well positioned as it enters Q2 after strengthening balance sheet

Cameron Reynolds, chief executive of VolitionRx Limited (NYSE AMERICAN:VNRX), tells Proactive London's Andrew Scott they're in a good place after again strengthening the balance sheet in recent weeks with a further $5 million in warrants exercised for cash. ''Total cash in hand that gives...

on 9/5/19

2 min read